TargeGen Selects Jak2 Inhibitor Lead (TG101348) For Clinical Development As A Potential Therapy For Myeloproliferative Diseases Including Polycythemia

... TargeGen, Inc., a biopharmaceutical company developing small molecule kinase inhibitor drugs, today announced that TG101348, an internally discovered, oral, potent, selective inhibitor of Jak2, has been designated as a lead drug for clinical development for the potential treatment of certain myeloproliferative diseases believed to be caused by a specific mutation (V617F) of Jak2. [click link for full article] ...